Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Healthtrust
McKesson
Dow
Johnson and Johnson
AstraZeneca
Farmers Insurance
Covington
Harvard Business School

Generated: April 25, 2018

DrugPatentWatch Database Preview

CHEMET Drug Profile

« Back to Dashboard

When do Chemet patents expire, and when can generic versions of Chemet launch?

Chemet is a drug marketed by Recordati Rare and is included in one NDA.

The generic ingredient in CHEMET is succimer. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the succimer profile page.
Drug patent expirations by year for CHEMET
Pharmacology for CHEMET
Drug ClassLead Chelator
Mechanism of ActionLead Chelating Activity
Medical Subject Heading (MeSH) Categories for CHEMET
Synonyms for CHEMET
(2R,3S)-2,3-disulfanylsuccinic acid
(2R,3S)-rel-2,3-Dimercaptosuccinic acid
(2S,3R)-2,3-bis(sulfanyl)butanedioic acid
(3S,2R)-2,3-disulfanylbutanedioic acid
(R*,S*)-2,3-Dimercaptobutanedioic acid
2,3-Dithio-meso-tartaric acid
2418-14-6 (parent cpd)
3-03-00-01033 (Beilstein Handbook Reference)
304-55-2
304D552
AC-1366
AC1MC4R8
AJ-45793
AK161810
AKOS015892684
API0004249
APRD01236 (Drugbankr
AX8137528
BC219408
BRD-K88701661-001-01-1
BRN 1725150
Butanedioic acid, 2,3-dimercapto-, (2R,3S)-rel-
Butanedioic acid, 2,3-dimercapto-, (R*,S*)-
C07598
C4H6O4S2
CCG-214189
CD-226
CHEBI:63623
CHEMBL1201073
Chemet (TN)
D00572
D01GYK
DB00566
Dim-sa
Dimercaptosuccinic acid
DMSA
DTXSID1023601
DX1U2629QE
EINECS 206-155-2
FCH3467898
HSDB 6783
Jsp005747
KS-00000GJ8
LS-147428
meso-2,3-Dimercaptobernsteinsaeure
meso-2,3-Dimercaptobernsteinsaure
meso-2,3-Dimercaptosuccinic acid
meso-2,3-Dimercaptosuccinic acid, ~98%
meso-Dimercaptosuccinic acid
MFCD00064799
MolPort-003-666-563
OR255576
Q-201748
Ro 1-7977
Ro-1-7977
SBB065802
SCHEMBL14941
SPECTRUM1505007
ST24034020
ST51007322
Succimer
Succimer (USAN/INN)
Succimer [USAN:INN:BAN]
Succimero
Succimero [INN-Spanish]
Succimerum
Succimerum [INN-Latin]
Succinic acid, 2,3-dimercapto-, meso-
Tin Dimercaptosuccinate
UNII-4S9JU7XF01 component ACTRVOBWPAIOHC-XIXRPRMCSA-N
UNII-DX1U2629QE
ZINC3831475

US Patents and Regulatory Information for CHEMET

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Recordati Rare CHEMET succimer CAPSULE;ORAL 019998-002 Jan 30, 1991 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
AstraZeneca
Deloitte
Federal Trade Commission
McKesson
US Army
Cipla
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.